非鳞状非小细胞肺癌-话题@MedSci

#非鳞状非小细胞肺癌#

32篇内容 | 2170人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1312151, encodeId=be1e1312151c9, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=46, createdTime=2021-06-28, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312150, encodeId=8aa41312150f3, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, objectType=article, longId=213120, objectId=686b21312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686b21312019, replyNumber=0, likeNumber=42, createdTime=2021-06-25, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686b21312019, moduleTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686b21312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312149, encodeId=fd411312149f4, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=43, createdTime=2021-06-17, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312148, encodeId=fdde13121481d, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, objectType=article, longId=207677, objectId=f31920e677cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31920e677cb, replyNumber=0, likeNumber=88, createdTime=2021-02-28, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31920e677cb, moduleTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31920e677cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312147, encodeId=dd32131214e13, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, objectType=article, longId=199076, objectId=63ee1990e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ee1990e68c, replyNumber=0, likeNumber=75, createdTime=2020-08-11, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ee1990e68c, moduleTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63ee1990e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312146, encodeId=3b6e131214634, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症, objectType=article, longId=192965, objectId=ea1f19296574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1f19296574, replyNumber=0, likeNumber=94, createdTime=2020-04-27, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1f19296574, moduleTitle=信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1f19296574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312145, encodeId=c67d131214537, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, objectType=article, longId=192235, objectId=15911922351b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15911922351b, replyNumber=0, likeNumber=63, createdTime=2020-04-16, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15911922351b, moduleTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15911922351b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312144, encodeId=83161312144d3, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=189823, objectId=597d18982326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597d18982326, replyNumber=0, likeNumber=60, createdTime=2020-03-13, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597d18982326, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597d18982326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312143, encodeId=4a2713121437a, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=Lancet oncol：派姆单抗联合培美曲塞-铂类治疗非鳞状非小细胞肺癌的患者自评预后, objectType=article, longId=187873, objectId=612818e8732b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=612818e8732b, replyNumber=0, likeNumber=78, createdTime=2020-02-13, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=612818e8732b, moduleTitle=Lancet oncol：派姆单抗联合培美曲塞-铂类治疗非鳞状非小细胞肺癌的患者自评预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=612818e8732b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312142, encodeId=626b1312142da, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=184290, objectId=431b184290f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=431b184290f9, replyNumber=0, likeNumber=61, createdTime=2019-12-08, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=431b184290f9, moduleTitle=罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=431b184290f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312141, encodeId=3205131214199, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=Lancet oncol：阿特珠单抗联合化疗作为非鳞状非小细胞肺癌患者一线疗法的疗效和安全性, objectType=article, longId=166796, objectId=7baf166e96c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7baf166e96c9, replyNumber=0, likeNumber=0, createdTime=2019-05-27, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7baf166e96c9, moduleTitle=Lancet oncol：阿特珠单抗联合化疗作为非鳞状非小细胞肺癌患者一线疗法的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7baf166e96c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312140, encodeId=07ff13121409b, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=2018年WCLC：Atezolizumab治疗IV期非鳞状非小细胞肺癌的有效性和安全性, objectType=article, longId=149961, objectId=921f1499613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=921f1499613d, replyNumber=0, likeNumber=81, createdTime=2018-09-30, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=921f1499613d, moduleTitle=2018年WCLC：Atezolizumab治疗IV期非鳞状非小细胞肺癌的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=921f1499613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312139, encodeId=6814131213960, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=NEJM：Atezolizumab一线治疗转移性非鳞状非小细胞肺癌, objectType=article, longId=140057, objectId=430314005e99, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430314005e99, replyNumber=0, likeNumber=0, createdTime=2018-06-07, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430314005e99, moduleTitle=NEJM：Atezolizumab一线治疗转移性非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=430314005e99)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312138, encodeId=fcef131213892, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=Sci Rep：超声引导下支气管内支气管刷检在周围型非鳞状非小细胞肺癌中的价值, objectType=article, longId=135089, objectId=d39b13508902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d39b13508902, replyNumber=0, likeNumber=80, createdTime=2018-04-14, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d39b13508902, moduleTitle=Sci Rep：超声引导下支气管内支气管刷检在周围型非鳞状非小细胞肺癌中的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d39b13508902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312137, encodeId=0fe3131213e4c, content=<a href='/topic/show?id=6c1099e74ad' target=_blank style='color:#2F92EE;'>#非鳞状非小细胞肺癌#</a>, objectTitle=NEJM：纳武单抗 vs 多西紫杉醇治疗晚期非鳞状非小细胞肺癌, objectType=article, longId=57641, objectId=38235e641a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38235e641a2, replyNumber=0, likeNumber=96, createdTime=2015-10-24, rootId=0, userName=weihongyv, userId=73a3403, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38235e641a2, moduleTitle=NEJM：纳武单抗 vs 多西紫杉醇治疗晚期非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38235e641a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非鳞状非小细胞肺癌

2020-05-29

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2021-06-28

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究

2021-06-25

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2021-06-17

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市

2021-02-28

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人

2020-08-11

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

信迪利单抗申请一线治疗非鳞状非小细胞肺癌新适应症

2020-04-27

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点

2020-04-16

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2020-03-13

zhouqu_8 (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

Lancet oncol：派姆单抗联合培美曲塞-铂类治疗非鳞状非小细胞肺癌的患者自评预后

2020-02-13

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

罗氏的PD-L1单抗Tecentriq获得FDA批准用于治疗转移性非鳞状非小细胞肺癌

2019-12-08

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

Lancet oncol：阿特珠单抗联合化疗作为非鳞状非小细胞肺癌患者一线疗法的疗效和安全性

2019-05-27

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

2018年WCLC：Atezolizumab治疗IV期非鳞状非小细胞肺癌的有效性和安全性

2018-09-30

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

NEJM：Atezolizumab一线治疗转移性非鳞状非小细胞肺癌

2018-06-07

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

Sci Rep：超声引导下支气管内支气管刷检在周围型非鳞状非小细胞肺癌中的价值

2018-04-14

weihongyv (审核中...)

前往app查看评论内容

#非鳞状非小细胞肺癌#

NEJM：纳武单抗 vs 多西紫杉醇治疗晚期非鳞状非小细胞肺癌

2015-10-24

科室
- - 订阅+
  - 更多科室
工具
服务